Case Report

Case report: combination of multiple intervention methods under bronchoscope for tracheal adenoid cystic carcinoma

Yan-Li Li1, Yan-Hong Liu1, Li-Hui Zhang1, Zhi-Dong Li1, Fang Yang2, Ya-Ji Yang1, Yi Xiao1

1First Department of Pulmonary and Critical Care Medicine, Yan’an Hospital of Kunming/Yan’an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan, P. R. China; 2Department of Pathology, Yan’an Hospital of Kunming/Yan’an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan, P. R. China

Received February 23, 2020; Accepted April 24, 2020; Epub June 15, 2020; Published June 30, 2020

Abstract: A 56-year-old male diagnosed with tracheal adenoid cystic carcinoma in 2009 was admitted to our department in February 2014 with complaints of progressively worsening breathlessness and wheezing. Computed tomography (CT) revealed a large tumor with near-complete obstruction of the distal trachea, and flexible bronchoscopy revealed a smooth, well-vascularized mass that almost completely obstructed the distal trachea. The patient was treated with high-frequency electrical snare, and about 2/3 of the foreign body was resected. After treatment, the patient’s dyspnea was clearly relieved. From 2014 to 2017, the patient underwent bronchoscopic high-frequency electrical snare, argon plasma coagulation (APC), and CO2 cryotherapy on several occasions due to local recurrence, and achieved good results. Surgical resection is the preferred treatment of adenoid cystic carcinoma. For patients who can’t undergo surgical resection at the time of consultation and/or have serious complications, bronchoscopic intervention is a new treatment method.

Keywords: Adenoid cystic carcinoma, fibrobronchoscopy, tracheal neoplasm

Introduction

Upper airway tumors are relatively rare and usually malignant [1]. Primary adenoid cystic carcinoma (ACC) is a low-grade malignant tumor that originates in the mucous gland or submucosal gland, and has an incidence of about 0.1/100,000 to 0.2/100,000 [2]. Tracheal adenoid cystic carcinoma (TACC) is a low-grade malignant tumor that originates in the trachea, and because it’s early clinical symptoms lack specificity, it is easily missed or misdiagnosed.

At present, surgical resection is considered as the first choice treatment of ACC. Endoscopic options for managing malignant airway obstruction, such as use of lasers and stents, are palliative and reserved for unresectable tumors or patients with contraindications to surgery [1]. ACC characteristically shows infiltrative growth and perineural invasion, and tends to metastasize to the lungs, bones, liver and brain [3]. Once distant metastasis occurs, most patients die within 2 years [4]. A case of TACC was treated with a variety of bronchoscopic interventions in our department, and achieved good results; which is reported as follows.

Case report

A 56-year-old man presented with complaints of progressively worsening breathlessness and wheezing in our department in February 2014. He had a history of TACC from about five years prior that was treated with chemoradiotherapy. Physical examination: the patient was conscious without cyanosis on his lips, nor jugular vein bulging. The three concave signs of inhalation were visible, the thorax was symmetric without deformity, the bilateral breathing momentum and tremor were of the same degree, the breathing sounds on both lungs were thick, and the neck and both lungs had wheezing sounds. No obvious abnormality was
found in the examination of the heart and abdomen, and no edema was found in either lower limbs. CT scan showed that the lower part of the lumen of the trachea was occluded by more than 95%. Bronchoscopy showed a smooth, well-vascularized mass that almost completely obstructed the distal trachea. The length of the obstruction was about 3 cm and blocked the trachea by about 90% (Figure 1A). After received high-frequency electric snare treatment, about 2/3 of the growth was resected (Figure 1B), and the patient’s dyspnea was significantly relieved. The histology of the biopsies was consistent with ACC (Figure 1C). From 2014 to 2017, the patient repeatedly underwent high-frequency electric snare, argon plasma coagulation (APC), and CO₂ cryotherapy in our department due to local recurrence, and achieved good results. In June 2018, the patient was re-admitted to our unit due to shortness of breath and wheezing. Chest CT scan (Figure 2) revealed that the wall of the lower trachea, carina region and the proximal segment of bilateral main bronchus were extensively and irregularly thickened, and the lumen was narrowed. The lumen of the proximal segment of the right main bronchus was clearly narrowed, with a minimum diameter of about 3 mm. There were multiple metastatic nodules and masses in both lungs and the pleural margins.

Figure 1. Bronchoscopic bronchopathy and the pathological examination of 2014. Before microscopic treatment (A): the endobronchial view seen on flexible bronchoscopy-vascularity of the new organism. The new organism is about 3 cm in length and blocks the trachea by about 90%. After microscopic treatment (B), the new organism is significantly smaller than before, and the bronchoscope can enter the left and right main bronchi and reveal unobstructed bronchial lumen of each section. (C) Photomicrographs of biopsy specimen (H&E, ×100) adenoid cystic carcinoma with a cribiform and tubular growth pattern infiltrates beyond the level of the trachea. The tumor cells are composed of basal cells and myoepithelial cells.

Figure 2. Chest CT scan: the walls of the lower part of general trachea, bulge area, and proximal part of the bilateral main bronchus are widely irregularly thickened and narrowed, which is obvious in the proximal section of the main bronchus with the lumen being significantly narrow with a minimum diameter of about 3 mm. There are multiple metastatic nodules and masses in both lungs and the pleural margins.
Tracheal adenoid cystic carcinoma bronchoscopic intervention

After treatment, the lumen diameter of the lower trachea was about 15 mm, the diameter of the right main bronchus was expanded to about 10 mm (Figure 3). The symptoms of breathing shortness and dyspnea in the patient were significantly relieved. The patient was repeatedly treated with high-frequency electrical snare, APC, laser ablation, and CO₂ cryotherapy due to tumor recurrence in our department within 9 years after the diagnosis of TACC and achieved good results. However, the patient eventually died of distant metastasis and lung infection in May 2019. This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Kunming Medical University. Written informed consent was obtained from all participants.

Discussion

Among the primary malignant tracheal tumors, mucoepidermoid carcinoma is the most common, followed by ACC, pleomorphic adenoma, acinar cell carcinoma, and epithelial-myoepithelial carcinoma [5]. TACC is a low-grade malignant tumor that originates in the trachea and is mainly located in the main bronchus visible by bronchoscopy [6]. Symptoms are usually attributable to the intraluminal component of the tumor causing an obstruction of the airway, potentially leading to stridor, dyspnoea, wheezing, haemoptysis, and cough [7]. The diagnosis of TACC mainly depends on imaging, bronchoscopy and pathological tissue biopsy. Bronchoscopy can directly observe the size and morphology of the tumor. Bronchoscopy also provides the specific information for operative planning, as measurements can be taken to assess whether a tumor is resectable based on its location and size [1].

The preferred primary treatment of ACC is surgical resection with clear margins and tracheal reconstruction when possible [7]. When tumors extensively involve the airway, are combined with distant metastasis, or the patient’s physical conditions can’t tolerate surgery; radiation therapy and bronchoscopy are common palliative treatment methods. Bronchoscopic inter-
Tracheal adenoid cystic carcinoma bronchoscopic intervention

Conventional therapy can effectively remove intratumoral tumors and temporarily/permanently relieve the airway obstruction caused by ACC [8]. The bronchoscopic therapies mainly include: endobronchial laser ablation, stent implantation, argon plasma coagulation (APC), CO₂ cryotherapy, rigid bronchoscopic recanalization and so on [9], which can effectively alleviate life-threatening airway obstruction. The patient in this study had life-threatening airway obstruction due to aggravated dyspnea at the time of his first visit to our department. Tumor growth involved a long part of the trachea and can’t be treated with surgery, so bronchoscopic intraluminal interventional treatment was the preferred and effective option.

ACC has a good prognosis but is known for late local recurrence and metastasis for which long-term follow up is indicated [10]. Patients can survive with tumors for many years. When airway stenosis recurs after treatment, bronchoscopic intervention can be performed several times to ensure airway patency. The patient in our case was diagnosed with TACC in 2009. Since 2014, this patient was repeatedly treated with various interventional therapies under bronchoscope for airway obstruction caused by local tumor recurrence, all of which achieved good results. The patient survived with the tumor for nearly 10 years. Eventually, he died of distant metastasis and lung infection.

Conclusions

ACC is a rare and slow-growing malignant tracheal tumor, which is less aggressive than squamous cell carcinoma. Nonspecific clinical symptoms are often the reason for late diagnosis or misdiagnosis. The diagnosis of ACC mainly depends on imaging, bronchoscopy, and pathological tissue biopsy. Surgical resection is the first choice for early treatment of ACC. When the tumor is non-resectable, bronchoscopic intervention would be an effective and acceptable option for these kinds of patients to obtain a promising prognosis. ACC is known for late local recurrence and metastasis for which long-term follow up is recommended.

Acknowledgements

This work was supported by Kunming Health Science and technology talents “thousand projects” training project (No. 2015SW-06); Yunnan Applied Basic Research Projects-Joint Special Project (No. 2017FE468 (-234)).

Disclosure of conflict of interest

None.

Address correspondence to: Yi Xiao, First Department of Pulmonary and Critical Care Medicine, Yan’an Hospital of Kunming/Yan’an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan, P. R. China. Tel: +86-871-6321-1287; Fax: +86-871-6311073; E-mail: yixiaodoc@163.com

References